Literature DB >> 31528688

Targeting the evolution of drug resistance in lung cancer.

Khyati Niral Shah1, Sourav Bandyopadhyay1.   

Abstract

Even in their intended disease subset, Epithelial Growth Factor Receptor tyrosine kinase inhibitors leave behind residual disease eventually resulting in acquired resistance. Our study indicates that this process is driven by Aurora Kinase A. Inhibition of Aurora signaling may prevent the onset of acquired resistance and counteract progressive disease.

Entities:  

Keywords:  Aurora kinase; EGFR; acquired resistance; and chromosomal instability; apoptosis; lung cancer; tumor evolution

Year:  2019        PMID： 31528688      PMCID： PMC6736160          DOI： 10.1080/23723556.2019.1603092

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  9 in total

1.  A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.

Authors:  Sreenath V Sharma; Diana Y Lee; Bihua Li; Margaret P Quinlan; Fumiyuki Takahashi; Shyamala Maheswaran; Ultan McDermott; Nancy Azizian; Lee Zou; Michael A Fischbach; Kwok-Kin Wong; Kathleyn Brandstetter; Ben Wittner; Sridhar Ramaswamy; Marie Classon; Jeff Settleman
Journal:  Cell       Date:  2010-04-02       Impact factor: 41.582

2.  Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

Authors:  Lecia V Sequist; Belinda A Waltman; Dora Dias-Santagata; Subba Digumarthy; Alexa B Turke; Panos Fidias; Kristin Bergethon; Alice T Shaw; Scott Gettinger; Arjola K Cosper; Sara Akhavanfard; Rebecca S Heist; Jennifer Temel; James G Christensen; John C Wain; Thomas J Lynch; Kathy Vernovsky; Eugene J Mark; Michael Lanuti; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Sci Transl Med       Date:  2011-03-23       Impact factor: 17.956

3.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

Review 4.  Aurora A kinase (AURKA) in normal and pathological cell division.

Authors:  Anna S Nikonova; Igor Astsaturov; Ilya G Serebriiskii; Roland L Dunbrack; Erica A Golemis
Journal:  Cell Mol Life Sci       Date:  2012-08-03       Impact factor: 9.261

5.  Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy.

Authors:  C E McCoach; G M Blumenthal; L Zhang; A Myers; S Tang; R Sridhara; P Keegan; R Pazdur; R C Doebele; D Kazandjian
Journal:  Ann Oncol       Date:  2017-11-01       Impact factor: 32.976

6.  Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.

Authors:  Khyati N Shah; Roma Bhatt; Julia Rotow; Julia Rohrberg; Victor Olivas; Victoria E Wang; Golzar Hemmati; Maria M Martins; Ashley Maynard; Jonathan Kuhn; Jacqueline Galeas; Hayley J Donnella; Swati Kaushik; Angel Ku; Sophie Dumont; Gregor Krings; Henry J Haringsma; Liliane Robillard; Andrew D Simmons; Thomas C Harding; Frank McCormick; Andrei Goga; Collin M Blakely; Trever G Bivona; Sourav Bandyopadhyay
Journal:  Nat Med       Date:  2018-11-26       Impact factor: 53.440

7.  Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Authors:  Tony S Mok; Yi-Long Wu; Myung-Ju Ahn; Marina C Garassino; Hye R Kim; Suresh S Ramalingam; Frances A Shepherd; Yong He; Hiroaki Akamatsu; Willemijn S M E Theelen; Chee K Lee; Martin Sebastian; Alison Templeton; Helen Mann; Marcelo Marotti; Serban Ghiorghiu; Vassiliki A Papadimitrakopoulou
Journal:  N Engl J Med       Date:  2016-12-06       Impact factor: 91.245

8.  Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.

Authors:  Aaron N Hata; Matthew J Niederst; Hannah L Archibald; Maria Gomez-Caraballo; Faria M Siddiqui; Hillary E Mulvey; Yosef E Maruvka; Fei Ji; Hyo-eun C Bhang; Viveksagar Krishnamurthy Radhakrishna; Giulia Siravegna; Haichuan Hu; Sana Raoof; Elizabeth Lockerman; Anuj Kalsy; Dana Lee; Celina L Keating; David A Ruddy; Leah J Damon; Adam S Crystal; Carlotta Costa; Zofia Piotrowska; Alberto Bardelli; Anthony J Iafrate; Ruslan I Sadreyev; Frank Stegmeier; Gad Getz; Lecia V Sequist; Anthony C Faber; Jeffrey A Engelman
Journal:  Nat Med       Date:  2016-02-01       Impact factor: 53.440

9.  Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.

Authors:  Collin M Blakely; Thomas B K Watkins; Wei Wu; Beatrice Gini; Jacob J Chabon; Caroline E McCoach; Nicholas McGranahan; Gareth A Wilson; Nicolai J Birkbak; Victor R Olivas; Julia Rotow; Ashley Maynard; Victoria Wang; Matthew A Gubens; Kimberly C Banks; Richard B Lanman; Aleah F Caulin; John St John; Anibal R Cordero; Petros Giannikopoulos; Andrew D Simmons; Philip C Mack; David R Gandara; Hatim Husain; Robert C Doebele; Jonathan W Riess; Maximilian Diehn; Charles Swanton; Trever G Bivona
Journal:  Nat Genet       Date:  2017-11-06       Impact factor: 38.330
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.